| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06.23 | Canacol Energy Ltd. Announces Meeting Results | 265 | GlobeNewswire (Europe) | CALGARY, Alberta, June 24, 2023 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) is pleased to announce that at the annual general meeting... ► Artikel lesen | |
| 24.06.23 | Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions | 691 | GlobeNewswire (Europe) | Press release - No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean of 4.2%... ► Artikel lesen | |
| 24.06.23 | Vir Biotechnology, Inc.: Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D | 316 | GlobeNewswire (Europe) | - Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis... ► Artikel lesen | |
| 24.06.23 | 89bio, Inc.: 89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine | 256 | GlobeNewswire (Europe) | - Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile - - SHTG Phase... ► Artikel lesen | |
| 24.06.23 | 89bio, Inc.: Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Li | 259 | GlobeNewswire (Europe) | - ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints - - New... ► Artikel lesen | |
| 24.06.23 | Biomea Fusion, Inc.: Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessio | 302 | GlobeNewswire (Europe) | Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing... ► Artikel lesen | |
| 24.06.23 | Jourdan Resources Inc.: Jourdan Announces Name Change to "Consolidated Lithium Metals Inc." | 477 | GlobeNewswire (Europe) | TORONTO, June 23, 2023 (GLOBE NEWSWIRE) -- JOURDAN RESOURCES INC. (TSXV: JOR; OTCQB: JORF; FRA: 2JR1) (the "Company") is pleased to announce that the Company has changed its name to "Consolidated... ► Artikel lesen | |
| 24.06.23 | INVENTIVA: Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association | 781 | GlobeNewswire (Europe) | Daix (France), Long Island City (New York, United States), June 24, 2023 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 3.285 |
| EVOTEC | 2.627 |
| TUI | 2.069 |
| NEL | 1.324 |
| BAYER | 1.144 |
| PLUG POWER | 1.136 |
| NVIDIA | 1.130 |
| RHEINMETALL | 1.054 |
| AMC ENTERTAINMENT | 1.034 |
| DEUTSCHE BANK | 951 |
| SIEMENS ENERGY | 930 |
| RENK GROUP | 873 |
| REDCARE PHARMACY | 725 |
| COMMERZBANK | 720 |
| HEIDELBERGER DRUCK | 699 |
| ALIBABA | 675 |
| VOLKSWAGEN | 667 |
| E.ON | 613 |
| BARRICK GOLD | 609 |
| BYD | 587 |
| RWE | 583 |
| SIEMENS | 562 |
| TESLA | 562 |
| DEUTSCHE LUFTHANSA | 556 |
| AIXTRON SE | 554 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
